graph EGM comparisons
nivolumab plus ipilimumabtitleplacebotitlenivolumab alonetitleipilimumab alonetitleCheckMate 069 (all population), 2015 NCT01927419 mML - L1 - all population 95/47CheckMate 067 (NI vs I ; all population), 2015 NCT01844505 mML - L1 - all population 314/315CheckMate 067 (NI vs N) EXPLORATORY, 2015 NCT01844505 mML - L1 - all population 314/316CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 NCT01927419 mML - L1 - BRAF mutant 23/10CheckMate 069 (BRAF wild type), 2015 NCT01927419 mML - L1 - BRAF wild 72/37CheckMate 915, 0 NCT03068455 mML - NA - all population -9/-9IMMUNED (NI vs N) EXPLORATORY, 2020 NCT02523313 mML - NA - all population 56/59IMMUNED (NI vs P ; all population), 2020 NCT02523313 mML - NA - all population 56/52

Pathology:  mML - L1 - all population;   mML - L1 - BRAF mutant;   mML - L1 - BRAF wild;   mML - NA - all population; 

mML - L1 - all populationmML - L1 - BRAF mutantmML - L1 - BRAF wildmML - NA - all population
CheckMate 069 (all population), 2015CheckMate 067 (NI vs I ; all population), 2015CheckMate 067 (NI vs N) EXPLORATORY, 2015CheckMate 069 (BRAF mutant) EXPLORATORY, 2015CheckMate 069 (BRAF wild type), 2015CheckMate 915, 0IMMUNED (NI vs N) EXPLORATORY, 2020IMMUNED (NI vs P ; all population), 2020
nivolumab plus ipilimumab8T1T1T1T1T1T1T1T1
placebo0T0
nivolumab alone0T0T0T0
ipilimumab alone0T0T0T0T0